Incyte's Zynyz Receives EU Approval for New Cancer Indication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy INCY?
Source: seekingalpha
Incyte Corp's stock fell 3.11% to $95.40, hitting a 20-day low amid a broader market decline with the Nasdaq-100 down 1.64% and the S&P 500 down 1.42%.
The company announced that its drug Zynyz (retifanlimab) has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). This marks the second indication for Zynyz in Europe, supported by data from the Phase 3 POD1UM-303 trial, which demonstrated significant effectiveness in patients who had not previously received systemic chemotherapy. Despite this positive news, Incyte's stock experienced a cautious market reaction, closing lower.
The approval of Zynyz not only expands Incyte's market potential but also reinforces its position in oncology. This development may attract investor interest, although the stock's recent performance suggests a need for careful monitoring of market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 95.270
Low
73.00
Averages
100.31
High
125.00
Current: 95.270
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
Incyte Q1 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Incyte's Q1 non-GAAP EPS of $1.81 beats expectations by $0.47, reflecting a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The total revenue for Q1 reached $1.27 billion, a 20% year-over-year increase, surpassing market expectations by $50 million, indicating robust performance and sustained demand in the biopharmaceutical sector.
- Product Sales Surge: Jakafi® net sales were $758 million, up 7%, while Opzelura® cream and the Hematology and Oncology portfolio saw sales increases of 20% and 116%, respectively, highlighting strong market acceptance and sales potential for new products.
- Positive Future Outlook: Incyte's guidance for total net sales in fiscal year 2026 is projected between $4.77 billion and $4.94 billion, reaffirming sales guidance across all categories, which demonstrates the company's confidence in future growth and sound strategic planning.
See More
Incyte Q1 Earnings Preview and Estimates
- Earnings Announcement Date: Incyte (INCY) is set to announce its Q1 earnings on April 28 before market open, with investors keenly awaiting the results that could impact stock performance.
- Earnings and Revenue Expectations: Analysts estimate an EPS of $1.34, reflecting a 15.5% year-over-year increase, while revenue is projected at $1.22 billion, up 16.2%, indicating the company's ongoing growth potential.
- Historical Performance Review: Over the past two years, Incyte has beaten EPS estimates 38% of the time and revenue estimates 88% of the time, showcasing the company's reliability in earnings announcements.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen no upward revisions but seven downward adjustments, while revenue estimates have experienced two upward revisions and five downward, reflecting a cautious market outlook on the company's future performance.
See More
Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
- First Chemotherapy-Free Option: Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy regimen approved in Australia, addressing a critical gap in treatment for patients with relapsed follicular lymphoma and expected to significantly enhance patient quality of life.
- Clinical Trial Results: In the global Phase 3 inMIND clinical study involving 652 patients, the Minjuvi combination regimen achieved a median progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control group, representing a 57% reduction in the risk of disease progression, relapse, or death, demonstrating significant efficacy.
- Meeting Patient Needs: Approximately 1,500 Australians are diagnosed with follicular lymphoma each year, and despite existing treatments, relapsed follicular lymphoma remains incurable; the approval of Minjuvi provides new hope for these patients, fulfilling the urgent need for effective therapies.
- Strategic Partnership Advancement: Specialised Therapeutics has entered into an exclusive distribution agreement with Incyte to commercialize Minjuvi in Australia, New Zealand, and Singapore, marking the company's ongoing commitment to meet patient needs in the Asia-Pacific region.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
FDA Approves Jakafi XR for Myelofibrosis and GVHD Treatment
- FDA Approval: Incyte announced that its Jakafi XR (ruxolitinib) has received FDA approval for the treatment of intermediate- or high-risk myelofibrosis (MF) and polycythemia vera (PV) patients who have had an inadequate response to hydroxyurea, reinforcing the company's leadership in hematology.
- Dosing Advantage: Jakafi XR is a once-daily extended-release formulation that provides comparable drug exposure to the twice-daily immediate-release formulation, offering a more convenient dosing option aimed at improving patient adherence and quality of life.
- Clinical Study Support: The FDA approval is based on clinical study results demonstrating that a single 55 mg Jakafi XR tablet taken once daily is bioequivalent to a 25 mg Jakafi tablet taken twice daily, indicating potential for similar clinical benefits.
- Patient Support Program: Incyte has launched the IncyteCARES program, providing personalized support, including financial assistance and educational resources, to eligible patients, aiming to eliminate barriers to access and further solidify its market position.
See More
Incyte Reports Strong Q1 2026 Earnings with Strategic Growth Plans
- Significant Sales Growth: Incyte reported net sales of $1.1 billion in Q1 2026, reflecting a 20% year-over-year increase, indicating strong demand across its hematology, oncology, and immunology product portfolio, which enhances overall performance.
- New Product Launch Plans: Management anticipates launching four new products over the next 12 months, including Jakafi XR and Opzelura, which will further strengthen the company's market competitiveness and drive revenue growth, particularly in the European market.
- Leadership Changes: Incyte appointed Suky Upadhyay as Chief Financial Officer and reorganized its U.S. commercial team to establish consistent standards and enterprise-level capabilities, aiming to prepare for product launches in 2026 and enhance operational efficiency.
- Reaffirmed Financial Guidance: The company reaffirmed its total net sales guidance for 2026 at $4.77 billion to $4.94 billion, with Jakafi sales expectations of $3.22 billion to $3.27 billion, demonstrating management's confidence in future performance and market demand.
See More
Incyte Q1 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Incyte's Q1 non-GAAP EPS of $1.81 beats expectations by $0.47, reflecting a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The total revenue for Q1 reached $1.27 billion, a 20% year-over-year increase, surpassing market expectations by $50 million, indicating robust performance and sustained demand in the biopharmaceutical sector.
- Product Sales Surge: Jakafi® net sales were $758 million, up 7%, while Opzelura® cream and the Hematology and Oncology portfolio saw sales increases of 20% and 116%, respectively, highlighting strong market acceptance and sales potential for new products.
- Positive Future Outlook: Incyte's guidance for total net sales in fiscal year 2026 is projected between $4.77 billion and $4.94 billion, reaffirming sales guidance across all categories, which demonstrates the company's confidence in future growth and sound strategic planning.
See More
Incyte Q1 Earnings Preview and Estimates
- Earnings Announcement Date: Incyte (INCY) is set to announce its Q1 earnings on April 28 before market open, with investors keenly awaiting the results that could impact stock performance.
- Earnings and Revenue Expectations: Analysts estimate an EPS of $1.34, reflecting a 15.5% year-over-year increase, while revenue is projected at $1.22 billion, up 16.2%, indicating the company's ongoing growth potential.
- Historical Performance Review: Over the past two years, Incyte has beaten EPS estimates 38% of the time and revenue estimates 88% of the time, showcasing the company's reliability in earnings announcements.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen no upward revisions but seven downward adjustments, while revenue estimates have experienced two upward revisions and five downward, reflecting a cautious market outlook on the company's future performance.
See More
Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
- First Chemotherapy-Free Option: Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy regimen approved in Australia, addressing a critical gap in treatment for patients with relapsed follicular lymphoma and expected to significantly enhance patient quality of life.
- Clinical Trial Results: In the global Phase 3 inMIND clinical study involving 652 patients, the Minjuvi combination regimen achieved a median progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control group, representing a 57% reduction in the risk of disease progression, relapse, or death, demonstrating significant efficacy.
- Meeting Patient Needs: Approximately 1,500 Australians are diagnosed with follicular lymphoma each year, and despite existing treatments, relapsed follicular lymphoma remains incurable; the approval of Minjuvi provides new hope for these patients, fulfilling the urgent need for effective therapies.
- Strategic Partnership Advancement: Specialised Therapeutics has entered into an exclusive distribution agreement with Incyte to commercialize Minjuvi in Australia, New Zealand, and Singapore, marking the company's ongoing commitment to meet patient needs in the Asia-Pacific region.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
